Trial · NCT07225387
Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial
NCT07225387, Phase 4, Recruiting, NephroNet, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial. Trials, record NCT07225387. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07225387
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial
- NCT number
- NCT07225387
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 30 participants, estimated
- Lead sponsor
- NephroNet, Inc.
- Conditions
- Lupus Nephritis
- Interventions
- Voclosporin
- First posted
- 2025-11-06
- Last updated
- 2025-11-06
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Primary Outcome Measure: Day 360 (12 Month) Outcome | 12 months | Proportion of Patients achieving and maintaining a Complete Clinical Renal Remission (CCRR) at 12 months. CCRR is defined as: UPCR≤ 0.5, eGFR≥60 and not \>20% below baseline, no rescue meds, sustained on repeat assessment 30 days later. |
| Secondary | Secondary Outcome Measure #1: Day 180 (6 Month) Outcome | 6 months | Proportion of Patients achieving and maintaining a Complete Clinical Renal Remission (CCRR) at 6 months. CCRR is defined as: UPCR≤ 0.5, eGFR≥60 and not \>20% below baseline, no rescue meds. |
| Secondary | Secondary Outcome Measure-#2: | 6 and 12 months | Proportion of Patients achieving and maintaining a Partial Clinical Renal Remission (PCRR) at 6 and 12 months. PCRR is defined as: A UPCR from a SPOT or 24-hour urine collection ≤50% of UPCR at baseline and eGFR not \>20% below baseline eGFR sustained on repeat measurement at Day 180 (6 months) and Day 360 (12 months). |
| Secondary | Secondary Outcome Measure-#3: | 12 months | Effectiveness of combination therapy on successful discontinuance of MMF. Examine the proportion of patients achieving CCRR who discontinued MMF after 90 days and compare to the proportion of patients achieving CCRR who continued MMF for the 360 Day (12 month) duration of the trial. Expectation is no difference in efficacy. |
| Secondary | Secondary Outcome Measure-#4: | 12 months | The proportion of patients requiring rescue therapy. Rescue therapy defined as: A patient requiring an increase in glucocorticoid (prednisone) to 1 mg/kg/d or intravenous solumedrol \>80 mg for over a week, or the addition of, or change to cyclophosphamide, eculizumab, rituximab, therapeutic plasmapheresis, or an experimental therapeutic. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07225387
GET https://conductscience.org/api/trials/v1/NCT07225387/registered